Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.71 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444359 | 0.86 | OPRM1 (0.68) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17438840 | 0.86 | OPRM1 (0.68) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17438816 | 0.85 | OPRM1 (0.67) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17438831 | 0.84 | OPRL1 (0.67) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17438620 | 0.84 | OPRM1 (0.65) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17439027 | 0.83 | OPRM1 (0.64) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17438976 | 0.83 | OPRM1 (1.00) | OPRM1OPRL1OPRK1HSD11B1 | |
| SCHEMBL17444107 | 0.83 | OPRM1 (0.70) | OPRM1OPRL1OPRK1 | |
| SCHEMBL17444109 | 0.83 | OPRM1 (0.70) | OPRM1OPRL1OPRK1 | |
| SCHEMBL17444086 | 0.82 | OPRM1 (0.63) | OPRM1OPRL1OPRK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | claimed |
| EP-3169665-B1 | SUBSTITUTED AZA-SPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-05-09 | — | — | EP | claimed |
| EP-3169665-A1 | SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2016008583-A1 | SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | claimed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 5/4885 |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.